{"id":"W4388421246","doi":"10.1016/j.jid.2023.09.235","title":"227 Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)","year":2023,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Eczema Area and Severity Index; Atopic dermatitis; Placebo; Medicine; Clinical endpoint; Internal medicine; Adverse effect; Randomized controlled trial; Gastroenterology; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008722994,0.0006250166,0.0012968,0.0002418673,0.00024221,0.000771025,0.0003563059,0.0007486159,0.002419257],"category_scores_gemma":[0.0005977639,0.0002793449,0.001214908,0.0001635826,0.0004320003,0.000490004,0.0001585992,0.001724859,0.0005967234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004200253,"about_ca_system_score_gemma":0.0004529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005334711,"about_ca_topic_score_gemma":0.001148517,"domain_scores_codex":[0.9997631,0.0001056697,0.00001576152,0.00003566838,0.00002968241,0.00005014874],"domain_scores_gemma":[0.9996849,0.00008379614,0.00006458778,0.00001871405,0.00002343687,0.000124458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6911385,0.02278054,0.007444428,0.001342096,0.001893408,0.0002298512,0.0001458996,0.00163904,0.05103926,0.0002358357,0.00517128,0.2169399],"study_design_scores_gemma":[0.6520551,0.3009783,0.03252793,0.0000851529,0.00118553,0.0005100776,0.00007127383,0.001966869,0.006311224,0.0002852332,0.003975128,0.00004823539],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926663,0.004705089,0.0002015748,0.0003468097,0.00009266689,0.0002822271,0.0004137038,0.00005812178,0.001233571],"genre_scores_gemma":[0.9941227,0.001976143,0.000528728,0.0005472817,0.0001711659,0.0002587426,0.0007876736,0.00001496682,0.001592624],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002419257,"threshold_uncertainty_score":0.008093238,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03726655205703843,"score_gpt":0.3259250980102791,"score_spread":0.2886585459532406,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}